Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00455 ...
Drug Name Loratadine
Molecular Weight 382.883
Molecular Formula C22H23ClN2O2
CAS Number 79794-75-5
SMILES CCOC(=O)N1CCC(CC1)=C1C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2
External Links
DRUGBANK DB00455
T3DB T3D2796
PubChem Compound 3957
PDR 1039
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Melting Point 135.0 ℃ 134-136 ℃ https://www.chemicalbook.com/ChemicalProductProperty_US_CB5283770.aspx
Water Solubility 1000.0 mg/L <1 mg/ml https://www.chemicalbook.com/ChemicalProductProperty_US_CB5283770.aspx

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
AUC 6.1 ng.h/ml 6.14 ng.h/ml PO, oral; immediate release formulation; DRUGBANK
AUC 49.1 ng.h/ml 49.1 ng.h/ml DRUGBANK
AUC 49.1 ng.h/ml 49.1 ng.h/ml immediate release formulation; Derivative; DRUGBANK
AUC 48.4 ng.h/ml 48.4 ng.h/ml Derivative; DRUGBANK
C Max 2.6 ng/ml 2.56 ng/ml PO, oral; immediate release formulation; DRUGBANK
C Max 3.7 ng/ml 3.72 ng/ml DRUGBANK
C Max 3.7 ng/ml 3.72 ng/ml immediate release formulation; Derivative; DRUGBANK
C Max 3.7 ng/ml 3.66 ng/ml Derivative; DRUGBANK
C Max 3.4 ng/ml 3.4±3.4 ng/ml PO, oral; adults; normal,healthy; The Pharmacological Basis of Therapeutics
C Max 4.1 ng/ml 4.1±2.6 ng/ml PO, oral; Active metabolite; adults; normal,healthy; The Pharmacological Basis of Therapeutics
C Max 4.0 ng/ml 4.0±2.1 ng/ml PO, oral; Active metabolite; Drug form; adults; normal,healthy; The Pharmacological Basis of Therapeutics
C Max 2.0 ng/ml 2.0±0.6 ng/ml PO, oral; Active metabolite; Drug form; adults; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 1.5 h 1-2 h DRUGBANK
T Max 3.5 h 3-4 h Active metabolite; DRUGBANK
T Max 1.1 h 1.14 h PO, oral; immediate release formulation; DRUGBANK
T Max 2.0 h 1.97 h DRUGBANK
T Max 2.0 h 1.97 h immediate release formulation; Derivative; DRUGBANK
T Max 2.0 h 1.97 h Derivative; DRUGBANK
T Max 2.0 h 2.0±0 h PO, oral; adults; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 2.6 h 2.6±2.9 h PO, oral; Active metabolite; adults; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 3.2 h 3.2±1.8 h PO, oral; Active metabolite; Drug form; adults; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 4.8 h 4.8±1.9 h PO, oral; Active metabolite; Drug form; adults; normal,healthy; The Pharmacological Basis of Therapeutics
Clearance 12.0 L/h/kg 12.0 L/h/kg Oral single dose; DRUGBANK
Clearance 9.0 L/h/kg 9.0 L/h/kg Oral single dose; DRUGBANK
Clearance 8.5 L/h/kg 142±57 ml/min/kg apparent clearance; hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia → ; The Pharmacological Basis of Therapeutics
Clearance 0.96 L/h/kg 14-18 ml/min/kg apparent clearance; hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ; The Pharmacological Basis of Therapeutics
Volume of Distribution 120.0 L/kg 120.0 L/kg DRUGBANK
Volume of Distribution 120.0 L/kg 120±80 L/kg Apparent volume of distribution; RD, renal impairment, Renal disease，including uremia → ; The Pharmacological Basis of Therapeutics
Volume of Distribution 26.0 L/kg 26.0 L/kg Apparent volume of distribution; The Pharmacological Basis of Therapeutics
Half-life 10.0 h ~10 h DRUGBANK
Half-life 20.0 h 20 h elimination half-life; DRUGBANK
Half-life 8.0 h 8±6 h RD, renal impairment, Renal disease，including uremia → ;chronic liver disease ↑ ; The Pharmacological Basis of Therapeutics
Half-life 22.5 h 21-24 h Active metabolite; The Pharmacological Basis of Therapeutics
Eliminate Route 40.0 % 40 % Urinary excretion; DRUGBANK
Eliminate Route 42.0 % 42 % Faeces excretion; DRUGBANK
Eliminate Route 0 % ~0 % Urinary excretion; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 98.0 % 97-99 % plasma proteins; DRUGBANK
Protein Binding 97.0 % 97 % The Pharmacological Basis of Therapeutics
Protein Binding 84.5 % 82-87 % Active metabolite; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for children 10.0 mg/day 10 mg/day PO, oral Claritin loratadine PDR
Max dose for adolescents 10.0 mg/day 10 mg/day PO, oral Claritin loratadine PDR
Max dose for geriatric 10.0 mg/day 10 mg/day PO, oral Claritin loratadine PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1